CLLS - Cellectis SA logo

Cellectis SA

CLLS

Cellectis SA develops gene-editing technologies for immuno-oncology, focusing on allogeneic chimeric antigen receptor T-cell therapies for various cancers, including acute lymphoblastic leukemia and non-Hodgkin's lymphoma.

โš•๏ธ Healthcare NASDAQ Listed 2007 $ USD
$1,000 invested 10 years ago โ†’$58today

Score Overview

1 Year
Score
Net Growth3.28%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth-22.42%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score3.8
Net Growth24.23%
Net Trend40%
Net Income Consistencyโ€”
Rev Growth-23.47%
Rev Trend40%
Revenue Consistencyโ€”
10 Years
Score
Net Growth-2.28%
Net Trend40%
Net Income Consistency
Rev Growth32.90%
Rev Trend40%
Revenue Consistency
All Time
Score
Net Growth-13x
Net Trend35%
Net Income Consistency
Rev Growth13x
Rev Trend53%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Cellectis SA has ranked, year by year

Measure
Fundamentals Window

Showing 1 year ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • CLLS

2012: 96.9% ยท 2021: 25.2% ยท free through 2021 ยท longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-01
$ 1.40โ€”
1 Year2025-10-01
$ 3.29-57.45%
5 Years2021-10-01
$ 12.69-88.97%
10 Years2016-09-30
$ 24.08-94.19%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 56M-$ 65M$ 166M
2025$ 72M-$ 67M$ 208M
2024$ 41M-$ 36M$ 260M
2023$ 755K-$ 101M$ 203M
2022$ 19M-$ 98M$ 97M
2021$ 73M-$ 86M$ 186M
2020$ 73M-$ 72M$ 268M
2019$ 15M-$ 90M$ 360M
2018$ 12M-$ 78M$ 451M
2017$ 25M-$ 99M$ 296M
2016$ 42M-$ 63M$ 290M
2015$ 55M-$ 22M$ 343M
2014$ 26M$ 136M
2013$ 22M-$ 84M$ 10M
2012$ 27M-$ 29M$ 28M
2011$ 20M-$ 30M$ 54M
2010$ 20M-$ 10M$ 31M
2009$ 17M-$ 5M$ 65M
2008$ 14M$ 185.15K$ 39M
IPO2007$ 4M-$ 4M$ 36M
CLLS - Cellectis SA logo

Cellectis SA fundamental performance

Between 2020 and 2025, revenue declined from $ 73M to $ 72M and net income went from -$ 72M to -$ 67M. Revenue increased in 2 of those 5 years; net income in 2.

Across Cellectis SA's full reported history, from 2007 to 2025, revenue grew from $ 4M to $ 72M and net income went from -$ 4M to -$ 67M. Revenue increased in 53% of the years measured; net income in 35%.

Cellectis SA currently holds a 5-year HDB Score of 3.8 out of 10. How the HDB Score is calculated.

Membership

Continue CLLSโ€™s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,813 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies